VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 29 filers reported holding VERONA PHARMA PLC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $6,240,000 | +1265.4% | 1,000,000 | +900.0% | 0.05% | +1050.0% |
| Q3 2019 | $457,000 | -10.4% | 100,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $510,000 | -21.5% | 100,000 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $650,000 | -32.6% | 100,000 | 0.0% | 0.01% | -40.0% |
| Q4 2018 | $965,000 | -22.9% | 100,000 | 0.0% | 0.01% | -9.1% |
| Q3 2018 | $1,251,000 | -8.4% | 100,000 | 0.0% | 0.01% | +37.5% |
| Q2 2018 | $1,366,000 | -31.7% | 100,000 | 0.0% | 0.01% | -60.0% |
| Q1 2018 | $2,000,000 | +76.4% | 100,000 | +5.1% | 0.02% | +66.7% |
| Q4 2017 | $1,134,000 | -2.7% | 95,149 | +25.3% | 0.01% | -7.7% |
| Q3 2017 | $1,165,000 | – | 75,917 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |